C12N 2310/343
Having patterns
Official title: having patterns, e.g. ==--==--==--
C12N2310/343 (Having patterns) appears on 222 US grants and 479 published applications in this corpus.
Search patents in C12N- Granted patents
- 222
- Published applications
- 479
- Assignees
- 116
- Inventors
- 656
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 3 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 1 | 2 |
| 2009 | 0 | 3 |
| 2010 | 2 | 2 |
| 2011 | 1 | 5 |
| 2012 | 3 | 2 |
| 2013 | 4 | 8 |
| 2014 | 3 | 14 |
| 2015 | 7 | 15 |
| 2016 | 14 | 27 |
| 2017 | 18 | 17 |
| 2018 | 14 | 22 |
| 2019 | 18 | 27 |
| 2020 | 14 | 27 |
| 2021 | 20 | 43 |
| 2022 | 21 | 51 |
| 2023 | 17 | 52 |
| 2024 | 19 | 57 |
| 2025 | 30 | 51 |
| 2026 | 16 | 49 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use8 Sep 2026US 12,729,377 B2Arrowhead Pharmaceuticals, Inc.
- Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression1 Sep 2026US 12,723,247 B2Alnylam Pharmaceuticals, Inc.
- Mannan binding lectin serine peptidase 2 (MASP2) IRNA compositions and methods of use thereof18 Aug 2026US 12,709,751 B2Alnylam Pharmaceuticals, Inc.
- RNAi agents for inhibiting expression of Beta-ENaC, compositions thereof, and methods of use16 Jun 2026US 12,655,428 B2Arrowhead Pharmaceuticals, Inc.
- Oligonucleotide compositions and methods thereof26 May 2026US 12,637,672 B2Wave Life Sciences Ltd.
- Pcsk9 irna compositions and methods of use thereof1 Oct 2026US 2026/0297586 A1Alnylam Pharmaceuticals, Inc.
- Compositions and methods for improved gene silencing17 Sep 2026US 2026/0272973 A1Atalanta Therapeutics, Inc.
- Modified sina molecules, methods and uses thereof17 Sep 2026US 2026/0275348 A1Phyzat Biopharmaceuticals, Lda.
- Oligonucleotides for htt-1a modulation10 Sep 2026US 2026/0265747 A1University of Massachusetts
- Sirna structures for high activity and reduced off target27 Aug 2026US 2026/0250686 A1Nitto Denko Corporation
Most cited
By later US patents
- Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation158US 8,124,745 B2Isis Pharmaceuticals, Inc. · 2012
- Interfering RNA molecules134US 7,452,987 B2Silence Therapeutics GmbH · 2008
- Modified iRNA agents105US 9,290,760 B2Alnylam Pharmaceuticals, Inc. · 2016
- Modified RNAi agents96US 9,796,974 B2Alnylam Pharmaceuticals, Inc. · 2017
- Interfering RNA molecules77US 9,222,092 B2Silence Therapeutics GmbH · 2015